Skip to main content
. 2024 Jul 4;38(9):1929–1937. doi: 10.1038/s41375-024-02333-4

Fig. 5. Impact of different gene mutations on overall survival in patients with de novo KMT2Ar AML and aged ≤60 years.

Fig. 5

A KRAS, B TP53, C comparison of overall survival of patients with any high-risk genes mutated (either KRAS-mut, or TP53-mut) and the rest of patients aged ≤60 years with de novo AML, D comparison of relapse-free survival of patients with any high-risk mutated genes (either KRAS-mut or TP53-mut) and the rest of patients aged ≤60 years with de novo AML. OS overall survival; RFS relapse-free survival; mut mutated; wt wildtype; HR high-risk genes (KRAS, TP53).